ACAD
31.07
-0.15
-0.48%
AEMD
0.25
-0.01
-4.48%
APRI
1.42
+0.09
+6.99%
ARNA
4.5
-0.06
-1.32%
ATEC
1.3
0.00
0.00%
CFN
59.59
+0.03
+0.04%
CNAT
5.98
+0.19
+3.28%
CRXM
0.21
0.00
0.00%
CYTX
0.48
0.00
0.00%
DXCM
61
+0.41
+0.68%
GNMK
13.3
+0.19
+1.45%
HALO
14.59
+0.44
+3.07%
ILMN
200.01
+2.15
+1.09%
INNV
0.21
+0.01
+4.95%
INO
8.5
0.00
0.00%
ISCO
0.06
+0.00
+7.83%
ISIS
69.88
+1.3
+1.90%
LGND
56.88
-0.54
-0.94%
LPTN
2.79
-0.1
-3.46%
MBVX
1.05
-0.1
-8.70%
MEIP
3.84
+0.12
+3.23%
MNOV
3.8
+0.01
+0.26%
MRTX
21.34
+0.88
+4.30%
MSTX
0.43
-0.02
-3.98%
NBIX
34.29
+0.9
+2.70%
NUVA
47.28
+0.81
+1.74%
ONCS
0.37
-0.02
-5.19%
ONVO
6.68
+0.19
+2.93%
OREX
5.34
-0.16
-2.82%
OTIC
31.75
+0.02
+0.06%
QDEL
24.45
+0.09
+0.37%
RCPT
112.71
-0.36
-0.32%
RGLS
18.63
+0.97
+5.49%
RMD
63.09
-0.23
-0.36%
SCIE
0.01
0.00
-9.60%
SPHS
0.47
+0.03
+6.59%
SRNE
10.73
+0.34
+3.27%
TROV
5.83
-0.02
-0.34%
VICL
1.05
+0.02
+1.46%
VOLC
17.98
+0.02
+0.11%
ZGNX
1.37
-0.02
-1.09%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

It Had to be You: Why Roche Was The Lone Suitor For Foundation

January 16, 2015 – 7:38 am | Edit Post
It Had to be You: Why Roche Was The Lone Suitor For Foundation

The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it was acquiring a majority interest in Foundation…

[[Click headline to continue reading.]]

It Had to be You: Why Roche Was The Lone Suitor For Foundation

January 16, 2015 – 7:38 am | Edit Post

The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it was acquiring a majority interest in Foundation…

[[Click headline to continue reading.]]

It Had to be You: Why Roche Was The Lone Suitor For Foundation

January 16, 2015 – 7:38 am | Edit Post

The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it was acquiring a majority interest in Foundation…

[[Click headline to continue reading.]]

It Had to be You: Why Roche Was The Lone Suitor For Foundation

January 16, 2015 – 7:38 am | Edit Post

The buzz from day one of the J.P. Morgan Healthcare Conference in San Francisco earlier this week was the announcement on Sunday night by Roche that it was acquiring a majority interest in Foundation…

[[Click headline to continue reading.]]

GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin

January 16, 2015 – 6:30 am | Edit Post
GenSpera Announces Positive Phase II Data for Investigational Agent Mipsagargin

First-in-Class Agent is Well Tolerated in Liver Cancer Patients

SAN ANTONIO, Jan. 16, 2015 /PRNewswire/ — GenSpera Inc. (OTCQB: GNSZ) today announced the encouraging results of a Phase II study of mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC). The results will be presented today (12:00 to 2:00 p.m. PST, Abstract #301) in a poster presentation at the 2015 Gastrointestinal Cancers Symposium in San Francisco, California. 

The Phase II results demonstrated that mipsagargin appears to be effective and is well-tolerated by HCC patients. Mipsagargin targets the enzyme prostate-specific membrane antigen (PSMA), which is highly expressed in tumor vasculature and prostate cancer cells. The Phase II study results (n=25) demonstrate that the prodrug effectively stabilizes progression of HCC by reducing blood flow within tumors while not affecting blood flow within normal tissues. 

“We are very encouraged with the positive results from this Phase II trial that demonstrate the tolerability and show indications of effectiveness of mipsagargin in advanced liver cancer patients,” said Craig Dionne, PhD, chief executive officer at GenSpera. “Mipsagargin is a first-in-class agent with a novel mechanism of action that is unlike any other drug being tested in patients with advanced liver cancer. Based on the results of this study, we intend to move forward with a large, global Phase III trial.”

Mipsagargin’s targeted approach differs from other vascular targeting agents by destroying established tumor vasculature rather than slowing the growth of new tumor blood vessels. The PSMA-targeting agent is designed to minimize side effects commonly observed with other therapies, while maximizing activity against tumors. 

“These results demonstrate the potential that mipsagargin has to treat one of the world’s deadliest cancers,” said Devalingam Mahalingam, MD, PhD, an oncologist at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio and principal investigator of the study. “In addition to observing prolonged disease stabilization in some patients, we noted anecdotal evidence that patients had improved performance status with much less fatigue and side effects associated with other anti-cancer therapeutics.”

With Phase II complete, GenSpera is designing a large, international Phase III study which will further define the anti-tumor potential of mipsagargin in liver cancer patients. More information on mipsagargin (G-202) can be found at www.genspera.com.

Hepatocellular carcinoma is the most common form of cancer that originates in the liver. In the United States, more than 33,000 new cases will be diagnosed in 2015. Globally, liver cancer is a primary public health issue with more than 700,000 people diagnosed and more than 600,000 deaths annually. It is the most common type of cancer in Southeast Asia and sub-Saharan Africa. A liver cancer diagnosis is often subsequent to other liver disease, making treatment of a highly compromised patient population particularly challenging.

Data Establishes Foundation for Continued Investigation
The Phase II study (Abstract #301) of mipsagargin was a multi-site, single arm study designed to assess time to progression and response rate to treatment. The study measured disease progression in 25 patients with advanced-stage liver disease and poor liver reserves who had failed first line treatment with sorafenib. Patients were administered episodic dosing of mipsagargin on the first three days of each treatment cycle. Study participants experienced a median time to progression of 4.2 months, nearly twice the time demonstrated in prior studies with placebo or ineffective agents. Thirty-five percent of patients received 5 or more cycles of treatment with an average time on study of 7.1 months.  Additionally, mipsagargin demonstrated decreased blood flow in liver tumors as measured by DCE-MRI.

About GenSpera
GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for the targeted release of drug candidates within tumors. GenSpera’s lead drug candidate, mipsagargin, was granted Orphan Drug designation by the US Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera’s technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.

 

SOURCE GenSpera

West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More

January 15, 2015 – 5:01 pm | Edit Post
West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More

Whew. J.P. Morgan is almost over. (The healthcare conference, that is, not the investment bank.) Opening the week’s proceedings at the Biotech Showcase, a satellite conference that features…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More

January 15, 2015 – 5:01 pm | Edit Post

Whew. J.P. Morgan is almost over. (The healthcare conference, that is, not the investment bank.) Opening the week’s proceedings at the Biotech Showcase, a satellite conference that features…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More

January 15, 2015 – 5:01 pm | Edit Post

Whew. J.P. Morgan is almost over. (The healthcare conference, that is, not the investment bank.) Opening the week’s proceedings at the Biotech Showcase, a satellite conference that features…

[[Click headline to continue reading.]]

West Coast Biotech Roundup: Tobira, Novartis, NantCell, & More

January 15, 2015 – 5:01 pm | Edit Post

Whew. J.P. Morgan is almost over. (The healthcare conference, that is, not the investment bank.) Opening the week’s proceedings at the Biotech Showcase, a satellite conference that features…

[[Click headline to continue reading.]]

Century-Old Drug Reverses Autism-Like Symptoms, University of California, San Diego (UCSD) Study

January 15, 2015 – 5:00 pm | Edit Post

Century-Old Drug Reverses Autism-like Symptoms in Fragile X Mouse Model Autism spectrum disorders (ASD) affect 1 to 2 percent of children in the United States. Hundreds of genetic and environmental factors have been shown to increase the risk of ASD. …